ISO 26825:2020 — User-Applied Labels for Anaesthetic Syringes: Colour Coding, Design and Performance Requirements

Introduction to ISO 26825:2020

ISO 26825:2020 specifies the colour, size, design, and performance requirements for user-applied labels on syringes containing drugs used during anaesthesia. This second edition cancels and replaces ISO 26825:2008, introducing significant revisions including updated colour coding for benzodiazepines, suxamethonium, muscle relaxant reversal drugs, and adrenaline, as well as new recommendations for ready-mixed drug labelling.

The standard applies to labels affixed to syringes just before use during anaesthesia, covering self-adhesive labels provided as individual units or in tape form. It addresses adhesive requirements, material properties, packaging, and detailed typographical specifications.

Colour Coding System and Drug Classification

The core of ISO 26825 is the comprehensive colour-coding scheme that assigns specific background colours to drug classes. This system enables rapid visual identification by anaesthetists in high-pressure clinical environments.

Key Engineering Design Requirements

ISO 26825 mandates specific physical and performance characteristics to ensure label legibility and durability in the demanding anaesthesia environment. Labels must be self-adhesive and withstand immersion in 50 % isopropanol solution for 5 minutes without moving, curling, or lifting at the edges.

The label dimensions are specified as 25 mm to 40 mm in length and 10 mm to 15 mm in width — a size carefully chosen to fit most syringe sizes without obscuring graduation marks. Letter height for drug names must be no less than 2.5 mm in a plain sans-serif bold font, with the drug name printed on the upper half of the label to allow space for concentration information below.

Special provisions cover heparin (white background with black border), protamine (black background with white diagonal stripes), and ready-mixed drugs. For suxamethonium and adrenaline, bold white lettering within a black bar running edge-to-edge across the upper half of the label is required for maximum contrast.

Regional Variations and Practical Implementation

The standard acknowledges that non-Roman alphabets may require adaptation of the typographic specifications. When the pharmacopoeia of a particular country necessitates the use of non-Roman characters, analogous principles of legibility should be applied. This flexibility ensures global applicability while maintaining the core safety benefits of standardized colour coding.

From an engineering perspective, the label material must be suitable for writing additional information (e.g., drug concentration) using a standard ball-point pen without smudging or blurring — a practical requirement that recognizes the dynamic nature of anaesthesia workflows where clinicians may need to annotate labels at the point of care.

Clinical Impact and Patient Safety Considerations

The standardized colour-coding system mandated by ISO 26825 has significant implications for patient safety during anaesthesia. In high-pressure clinical environments such as operating theatres and emergency departments, anaesthetists must rapidly identify and administer multiple drugs with precision. Studies on medication errors in anaesthesia have shown that misidentification of syringe contents is a preventable source of adverse events. The unambiguous assignment of specific colours to drug classes reduces cognitive load and minimizes the risk of wrong-drug administration, particularly during critical events when time is limited. The standard’s requirement for bold sans-serif lettering with minimum heights and the prohibition of all-capitals presentation further enhances readability under stressful conditions. The inclusion of tall-man lettering for distinguishing similar drug names addresses a well-documented source of medication errors — look-alike, sound-alike drug names. From a human factors engineering perspective, ISO 26825 represents an evidence-based approach to error reduction through standardized visual communication.

ISO 26825 also addresses the special case of ready-mixed drugs in a single ampoule. For example, neostigmine and glycopyrrolate combined in one preparation should be labelled reflecting the intended action — muscle relaxant reversal — with the background colour of warm red and white diagonal stripes. The standard recommends that either two separate labels may be used or a single label reflecting the dominant pharmacological action. This pragmatic approach acknowledges the clinical reality of polypharmacy in anaesthesia while maintaining the integrity of the colour-coding system.

Compliance Testing and Verification Methods

Each requirement in ISO 26825 is paired with a specific verification method, ensuring unambiguous compliance assessment. Visual inspection is specified for colour and design requirements, functional testing for adhesive performance and writability, and physical measurement for dimensions and letter heights. The adhesive immersion test using 50 % isopropanol solution is particularly noteworthy as it simulates the clinical environment where syringes may be exposed to alcohol-based disinfectants and skin preparation solutions. Polyethylene is specified as the test syringe material because its poor adhesion properties represent a worst-case scenario — if the label adheres to polyethylene after isopropanol exposure, it will perform adequately on typical clinical syringe materials. This engineering approach to testing — selecting the most challenging conditions rather than average conditions — ensures a safety margin in real-world performance.

Frequently Asked Questions